Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24607751 | 0.90 | CYP2D6 (0.42) | CYP2D6SMN1; SMN2TSHRPIK3CDUSP2 | |
| SCHEMBL24508733 | 0.81 | CYP2D6 (0.38) | CYP2D6SMN1; SMN2TSHRPIK3CDUSP2 | |
| SCHEMBL24508755 | 0.80 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2TSHRUSP2CYP1A2 | |
| SCHEMBL22305208 | 0.80 | CYP2D6 (0.53) | CYP2D6SMN1; SMN2TSHRPIK3CDUSP2 | |
| SCHEMBL27281654 | 0.80 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2TSHRPIK3CDUSP2 | |
| SCHEMBL27281826 | 0.80 | CYP3A4 (0.48) | CYP2D6TSHRUSP2CYP1A2HIF1A | |
| SCHEMBL19504447 | 0.79 | KDM1A (0.31) | HSD17B10 | |
| SCHEMBL26445327 | 0.79 | CYP2D6 (0.37) | CYP2D6SMN1; SMN2TSHRPIK3CDUSP2 | |
| SCHEMBL16999001 | 0.76 | CYP2D6 (0.45) | CYP2D6SMN1; SMN2TSHRUSP2CYP1A2 | |
| SCHEMBL23770532 | 0.76 | CYP2D6 (0.45) | CYP2D6SMN1; SMN2TSHRUSP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228500-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228500-A1 | THERAPEUTIC CONJUGATES | CD47, CD44, EPCAM | CYP2D6 3813/4885SMN1; SMN2 620/4885TSHR 1880/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885TSHR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.